Evidence map›Paper›PMID 42351198›Full record

SynthesisSystematic reviews2026

Circulating microRNA dysregulation in hypertrophic cardiomyopathy, arrhythmogenic cardiomyopathy, and dilated cardiomyopathy: a systematic review.

Laurens Léger, Sabina Ferron, Nele S Pauwels, Franne Lingier, Alba Rodriguez-Muñoz, Mora Murri-Pierri, Jolanda van Hengel, Martina Calore

Abstract readSystematic Review
In one paragraph

Synthesis in Systematic reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Laurens Léger *Medical Cell Biology Research Group, Department of Human Structure and Repair, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.
Sabina Ferron *Department of Biology, Padova University, Padua, Italy.
Nele S PauwelsKnowledge Centre for Health Ghent, Ghent University Hospital, Ghent, Belgium.
Franne LingierMedical Cell Biology Research Group, Department of Human Structure and Repair, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.
Alba Rodriguez-MuñozDepartment of Endocrinology and Nutrition, Virgen de la Victoria University Hospital and Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Malaga, Spain.
Mora Murri-PierriDepartment of Endocrinology and Nutrition, Virgen de la Victoria University Hospital and Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Malaga, Spain.
Jolanda van HengelMedical Cell Biology Research Group, Department of Human Structure and Repair, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium. Jolanda.VanHengel@ugent.be.
Martina CaloreDepartment of Biology, Padova University, Padua, Italy. martina.calore@unipd.it.ORCID 0000-0003-4751-1476

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypertrophic cardiomyopathy (HCM), arrhythmogenic cardiomyopathy (ACM) and dilated cardiomyopathy (DCM) represent the most frequent structural heart disorders. Due to the complexity of their diagnosis and the frequent occurrence of sudden cardiac death as the first manifestation, these diseases impose a relevant socio-economic burden, highlighting the urgent need for novel disease-specific biomarkers. Here, we assess the potential of microRNAs (miRNAs) as non-invasive predictors for HCM, ACM, and DCM. Electronic databases were systematically searched using relevant keywords pertaining to the disorders and miRNAs. To minimize spurious associations, only studies reporting the area under the curve (AUC) and including healthy controls were taken into account, resulting in the selection of 19 papers for further analyses. miR-29a-3p, miR-185-5p, and miR-454-3p were found overexpressed in HCM, ACM, and DCM, respectively, across different studies. Assessment of the correlation between circulating miRNA levels and cardiac features or genetic background failed to detect consistent profiles among different studies. Thus, further investigations employing consistent approaches and larger cohorts are required to validate the clinical utility of circulating miRNAs as non-invasive biomarkers for these structural cardiomyopathies.Systematic review registration PROSPERO CRD42023330236.

Indexed as

Arrhythmogenic Right Ventricular DysplasiaCardiomyopathy, DilatedCardiomyopathy, HypertrophicCirculating MicroRNAMicroRNAsBiomarkersHumansBiomarkersCirculating MicroRNAMicroRNAsArrhythmogenic cardiomyopathyBiomarkersDilated cardiomyopathyHeart failureHypertrophic cardiomyopathyInherited cardiomyopathyMiRNAs

Identifiers

PMID42351198
PMCPMC13560302

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.